[1] Weng Q, et al. Zosurabalpin: a novel tethered macrocyclic peptide antibiotic that kills carbapenem-resistant Acinetobacter baumannii. MedComm (2020). 2024 Aug 11;5(8):e696. DOI:
10.1002/mco2.696[2] Skudlarek JW, et al. Cerastecin Inhibition of the Lipooligosaccharide Transporter MsbA to Combat Acinetobacter baumannii: From Screening Impurity to In Vivo Efficacy. J Med Chem. 2024 Sep 12;67(17):15620-15675. DOI:
10.1021/acs.jmedchem.4c01277[3] Zampaloni C, et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature. 2024 Jan;625(7995):566-571. doi: 10.1038/s41586-023-06873-0. Epub 2024 Jan 3. Erratum in: Nature. 2024 Jul;631(8022):E17. DOI:
10.1038/s41586-023-06873-0[4] Hawser, S, et al. 2131. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Clinical Acinetobacter Isolates from China. Open Forum Infect Dis 2023, 10, ofad500.1754.